Alterity Granted Patent in Europe for Neurodegenerative Diseases including Parkinson’s, Alzheimer’s

 Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the European Patent Office has granted Alterity a new composition of matter patent.

The patent secures broad protection over a new class of iron chaperone drug candidates for treating major neurodegenerative diseases. It is well established that excess iron in the brain is implicated in the pathology of many important neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases.¹

^{https://www.biospace.com/article/releases/alterity-therapeutics-granted-new-composition-of-matter-patent-in-europe-for-neurodegenerative-diseases-including-parkinson-s-and-alzheimer-snew-patent-covers-over-150-novel-compounds/}